Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125061) titled 'Multimodal Ablation Combined with Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC' on May 20.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Langfang Campus of Chinese Academy of Medical Sciences Cancer Hospital
Condition:
Non-Small-Cell Lung Cancer
Intervention:
Intervention group:(1) Multimodal ablation therapy.
(2) Neoadjuvant therapy: Neoadjuvant tislelizumab (200 mg, IV, Q3W) combined with chemotherapy will be administered within 2 weeks after ablation. For patients with squamous NSCLC, cisplatin or carboplatin combined with paclitaxel will be used...